|
1
|
Cuypers HT, Selten G, Quint W, Zijlstra M,
Maandag ER, Boelens W, van Wezenbeek P, Melief C and Berns A:
Murine leukemia virus-induced T-cell lymphomagenesis: Integration
of proviruses in a distinct chromosomal region. Cell. 37:141–150.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song JH, Padi SK, Luevano LA, Minden MD,
DeAngelo DJ, Hardiman G, Ball LE, Warfel NA and Kraft AS: Insulin
receptor substrate 1 is a substrate of the Pim protein kinases.
Oncotarget. 7:20152–20165. 2016.PubMed/NCBI
|
|
3
|
Natarajan K, Xie Y, Burcu M, Linn DE, Qiu
Y and Baer MR: Pim-1 kinase phosphorylates and stabilizes 130 kDa
FLT3 and promotes aberrant STAT5 signaling in acute myeloid
leukemia with FLT3 internal tandem duplication. PLoS One.
8:e746532013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holder SL and Abdulkadir SA: PIM1 kinase
as a target in prostate cancer: Roles in tumorigenesis, castration
resistance, and docetaxel resistance. Curr Cancer Drug Targets.
14:105–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 66:7–30. 2017. View Article : Google Scholar
|
|
7
|
Mizokami A and Namiki M: Reconsideration
of progression to CRPC during androgen deprivation therapy. J
Steroid Biochem Mol Biol. 145:164–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J,
Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor
regulates a distinct transcription program in androgen-independent
prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grasso CS, Wu YM, Robinson DR, Cao X,
Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC,
et al: The mutational landscape of lethal castration-resistant
prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC,
Attard G, et al: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shah N, Pang B, Yeoh KG, Thorn S, Chen CS,
Lilly MB and Salto-Tellez M: Potential roles for the PIM1 kinase in
human cancer-a molecular and therapeutic appraisal. Eur J Cancer.
44:2144–2151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rimon E, Sasson R, Dantes A, Land-Bracha A
and Amsterdam A: Gonadotropin-induced gene regulation in human
granulosa cells obtained from IVF patients: Modulation of genes
coding for growth factors and their receptors and genes involved in
cancer and other diseases. Int J Oncol. 24:1325–1338.
2004.PubMed/NCBI
|
|
13
|
Cibull TL, Jones TD, Li L, Eble JN,
Baldridge Ann L, Malott SR, Luo Y and Cheng L: Overexpression of
Pim-1 during progression of prostatic adenocarcinoma. J Clin
Pathol. 59:285–288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brasó-Maristany F, Filosto S, Catchpole S,
Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L,
Gazinska P, Liccardi G, et al: PIM1 kinase regulates cell death,
tumor growth and chemotherapy response in triple-negative breast
cancer. Nat Med. 22:1303–1313. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu J, Zhang T, Wang T, You L and Zhao Y:
PIM kinases: An overview in tumors and recent advances in
pancreatic cancer. Future Onco. 10:865–876. 2014. View Article : Google Scholar
|
|
16
|
He HC, Bi XC, Zheng ZW, Dai QS, Han ZD,
Liang YX, Ye YK, Zeng GH, Zhu G and Zhong WD: Real-time
quantitative RT-PCR assessment of PIM-1and hK2 mRNA expression in
benign prostate hyperplasia and prostate cancer. Med Oncol.
26:303–308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen WW, Chan DC, Donald C, Lilly MB and
Kraft AS: Pim family kinases enhance tumor growth of prostate
cancer cells. Mol Cancer Res. 3:443–451. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Zhang T, Tang H, Zhang S, Liu M, Ren
D and Niu Y: Overexpression of PIM-1 is a potential biomarker in
prostate carcinoma. J Surg Oncol. 92:326–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van der Poel HG, Zevenhoven J and Bergman
AM: Pim1 regulate androgen-dependent survival signaling in prostate
cancer cells. Urol Int. 84:212–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald
WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ and Logan
SK: Phosphorylation of the androgen receptor by PIM1 in hormone
refractory prostate cancer. Oncogene. 32:3992–4000. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim O, Jiang T, Xie Y, Guo Z, Chen H and
Qiu Y: Synergism of cytoplasmic kinases in IL6-induced
ligand-independent activation of androgen receptor in prostate
cancer cells. Oncogene. 23:1838–1844. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu JL, Leong PK, Ho YF, Hsu LC, Lu PH,
Chen CS and Guh JH: Pim-1 knockdown potentiates paclitaxel-induced
apoptosis in human hormone-refractory prostate cancers through
inhibition of NHEJ DNA repair. Cancer Lett. 319:214–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Kim J, Roh M, Franco OE, Hayward
SW, Wills ML and Abdulkadir SA: Pim1 kinase synergizes with c-MYC
to induce advanced prostate carcinoma. Oncogene. 29:2477–2487.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morishita D, Katayama R, Sekimizu K,
Tsuruo T and Fujita N: Pim kinases promote cell cycle progression
by phosphorylating and down-regulating p27Kip1 at the
transcriptional and posttranscriptional levels. Cancer Res.
68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Holder S, Zemskova M, Zhang C, Tabrizizad
M, Bremer R, Neidigh JW and Lilly MB: Characterization of a potent
and selective small-molecule inhibitor of the PIM1 kinase. Mol
Cancer Ther. 6:163–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu XF, Li J, Vandervalk S, Wang Z,
Magnuson NS and Xing PX: PIM-1-specific mAb suppresses human and
mouse tumor growth by decreasing PIM-1 levels, reducing Akt
phosphorylation, and activating apoptosis. J Clin Invest.
119:362–375. 2009.PubMed/NCBI
|
|
27
|
Zemskova M, Sahakian E, Bashkirova S and
Lilly M: The PIM1 kinase is a critical component of a survival
pathway activated by docetaxel and promotes survival of
docetaxel-treated prostate cancer cells. J Biol Chem.
283:20635–20644. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakagawa S and Cuthill IC: Effect size,
confidence interval and statistical significance: A practical guide
for biologists. Biol Rev Camb Philos Soc. 82:591–605. 2007.
View Article : Google Scholar : PubMed/NCBI
|
